1. Giurgea C.  The «nootropic» approach to thepharmacology of the intergrative activity of the brain. Cond Reflex 1973; 8: 108–15.
2. Eckert A, Keil U et al. Effects of Ginkgo biloba extract on mitochondrial function and oxidative stress. Pharmacopsych  2003; 36 (1): S15–S23.
3. Mairs I, Marocci L et al. Peroxyl  radical scavenging activity of Ginkgo biloba Extract EG 761. Biochem Pharmacol 1995; 49: 1649–55.
4. Noda Y, Anzai K et al. Hydroxyl and superoxide anion radical scavenging activities of natural source antioxidants using the computerized JES-FR30 ESR spectrometer system. Biochem Mol Biol Int 1997; 42: 35–44.
5. Bridi R, Crossetti FP et al. The antioxidant activity of extract Ginkgo biloba EGb761 in  rats. Phytother Res 2001; 15: 449–51.
6. Abdel-Kader R, Hauptmann S, Keil U et al. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761H). Pharmacol Res 2007; 56: 493–502.
7. Sastre J, Lloret A et al. Ginkgo biloba extract EGb 761 protects against mitochondrial aging in rat brain and  in the liver. Cell Mol Biol 2002; 48: 685–92.
8. Auguet M, DeFeudis FV, Clostre F, Deghenghi R. Effects of an extract of Ginkgo biloba on rabbit isolated aorta. Gen Pharmacol 1982; 13 (3): 225–30.
9. Kehr J, Yoshitake S, Ijiri S et al. Ginkgo biloba leaf extract (EGb 761H) and its specific acylated flavonol constituents increase dopamine and acetylcholine levels in the rat medial prefrontal cortex: possible implications for the cognitive enhancing properties of EGb 761H. Int Psychogeriatr 2012; 1 (Suppl. 24): S25–34.
10. Арушанян Э.Б., Бейер Э.В. Ноотропные свойства препаратов гинкго билоба. Эксперим. и клин. фармакология. 2008; 71 (4): 57–63.
11. Williams B, Watanabe CM, Schultz PG  et al. Agerelated effects of Ginkgo biloba extract on synaptic plasticity and excitability. Neurobiol Aging 2004; 25 (7): 955–62.
12. Yoshitake T, Yoshitake S, Kehr J. The Ginkgo biloba extract EGb 761H and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex. Br J Pharmacol 2010; 159: 659–68.
13. Wu Y, Wu Z, Butko P et al. Amyloid-binduced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761H and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci 2006; 26: 13102–13.
14. Luo Y, Smith JV, Paramasivam V et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA 2002; 99 (19): 12197–202.
15. Tchantchou F, Xu Y, Wu Y et al. EGb 761H enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer’s disease. FASEB J 2007; 21: 2400–8.
16. Költringer P, Langsteger W, Ober O. Dose-dependent hemorheological effects and microcirculatory modifications following intravenous administration of Ginkgo biloba special extract EGb 761. Clin Hemorheol 1995; 15: 649–56.
17.  Koch E. Inhibition of platelet activating factor (PAF)-induced aggregation of  human  thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts. Phytomed 2005; 12: 10–6.
18. Ahlemeyer B, Krieglstein J. Neuroprotective effects of Ginkgo biloba extract. Cell Mol Life Sci 2003; 60 (9): 1779–92.
19. Weinmann S, Roll S et al. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. J BMC Geriatr 2010; 10: 14.
20. Amieva H, Meillon C et al. Ginkgo biloba Extract and long-term cognitive decline: a 20-year follow-up population-based study. Ploss One 2013; 8 (1): е52755.
21. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment in  dementia. Dement  geriatr Cogn Disord 2000; 11: 230–7.
22. Matcau L.  Clinical trial with Bilobil in patients with mild and moderate cognitive impairment.  Krka. Data on File 2003. 
23. Захаров В.В. Принципы ведения пациентов с когнитивными нарушениями без деменции. РМЖ. 2008; 16 (12): 1645–9. 
24.  Яхно Н.Н., Захаров В.В., Локшина А.Б. и др. Танакан (EGb 761) в терапии умеренных когнитивных нарушений (мультицентровое исследование). Журн.  неврологии и психиатрии. 2006; 12: 41–6.
25. Yancheva S, Ihl R, Nikolova R et al. Ginkgo biloba extract EGb 761R, donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: A randomised, double-blind, exploratory trial. Aging Ment Health 2008; 13: 183–90.
26. Hoerr R. Treatment effects of  EGb 761 and cholinesterase inhibitors – why available studies do not demonstrate superiority of the latter. Phytomed 2005; 12: 598–600. 
27. Mazza M, Capuano A et al. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer’s dementia in a randomized placebo-controlled double-blind study. Eur J Neurol 2006; 13: 981–5.
28. Hofferberth B. Arzneimittelforschung 1989; 39: 918.
29. Itil TM, Eralp E et al. Central nervous System effects of Ginkgo biloba, a plant extract. Am J Ther 1996; 3: 63–73.
30. Hann  J, Hoerr R. Delay in progression of dependency and need of care of dementia patients treated with Ginkgo biloba Special Extract EG 761. Wien Med Wochenschr 2004; 154: 21–2.
31. Ihl R, Kretschmar C et al. About evalution of nootropics for the practice.  Nervenarzt 1997; 68: 853–61.
32. Яхно Н.Н., Захаров В.В., Страчунская Е.Я. и др. Лечение недементных когнитивных нарушений у пациентов с артериальной гипертензией и церебральным атеросклерозом (По данным российского мультицентрового исследования «ФУЭТЕ»). Лекарственные препараты в неврологии. 2012; с. 49–55.
33. Andrieu S, Gillette S, Amouyal K et al. Association of Alzheimer’s disease onset with ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J Gerontol A Biol Sci Med Sci 2003; 58: 372–7.
34. DeKosky ST, Williamson JD, Fitzpatrick AL et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA  2008; 300 (19): 2253–62. 
35. Vellas B, Coley N, Ousset PJ et al.  Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 2012; 11 (10): 851–9.
36. Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG. Effects of nonsteroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer’s Disease Anti-inflammatory Prevention Trial. Int J Geriatr Psych 2012; 27: 364–74.
37. Raschetti R, Albanese E, Vanacore N, Maggini M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 2007; 4: е338.
38. Марута Н.А., Явдак И.А. Применение Билобила форте в лечении пациентов с дисциркуляторной энцефалопатией (аспекты эффективности и безопасности). Междунар. неврол. журн.  2009; 4 (26).
39. Левин О.С. Подходы к диагностике и лечению когнитивных нарушений при дисциркуляторной энцефалопатии. Трудный пациент. 2008; 11: 14–20.
40. Бугрова С.Г. Эффективность Билобила форте у больных с хронической ишемией мозга I стадии. РМЖ. 2009; 17 (4).
41. Шахпаронова Н.В., Кадыков А.С. Место препарата Билобил в комплексной терапии сосудистых заболеваний головного мозга. Лiки Украiни. 2010; 9: 54–6. 
42.  Meyer B. Etude multucentrique des accouphenes. Ann Otolaryngol 1986; 103: 185–8.
43. Morgenstern C, Biermann E. The efficacy of Ginkgo biloba Special Extract EG 761 in patients with tinnitus. Int J Clin Farmacol Ther 2002; 40: 188–97.
44. Kennedy DO, Scholey AB et al. The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacol 2000; 151: 416–23.
45. Wolf HR. Does Ginkgo biloba Special Extract EG 761 provide additional effects on coagulation and bleeding when added  to acetylsalicylic 500 mg daily? Drugs R D 2006; 7 (3): 163–72.
46. Herrschaft H, Nacu A, Likhachev S et al. Ginkgo biloba extract EGb 761 (R) in dementia with neuropsychiatric features: A randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of  240 mg. J Psychiatr Res 2012; 46: 716–23. 
47. Hofferberth B. Munch Med Wochnschr 1991; 133: 30.
48. Janssen IM, Sturtz S, Skipka G et al. Ginkgo biloba in Alzheimer’s disease: a systematic review. Wien Med Wochenschr 2011; 160: 539–46.
49. Давыдова Т.А., Густов А.В. и др. Применение танакана в комплексном лечении вестибуло-атаксического синдрома у больных с хронической ишемией головного мозга. Журн.  неврологии и психиатрии. 2011; 4: 85–6.
50. Яхно Н.Н., Суслина З.А., Грибачева И.А. и др. Влияние препарата Билобил форте на умеренные когнитивные нарушения у пациентов с дисциркуляторной энцефалопатией 1–2 стадии. Клинико-нейропсихологическое исследование. РМЖ. 2007.

Е.А.Катунина 

ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва